BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen CP. Role of Radiotherapy in the Treatment of Hepatocellular Carcinoma. J Clin Transl Hepatol. 2019;7:183-190. [PMID: 31293919 DOI: 10.14218/jcth.2018.00060] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Pan F, Lin X, Hao L, Wang T, Song H, Wang R. The Critical Role of Ferroptosis in Hepatocellular Carcinoma. Front Cell Dev Biol 2022;10:882571. [DOI: 10.3389/fcell.2022.882571] [Reference Citation Analysis]
2 Hassan SA, Ali AAH, Sohn D, Flögel U, Jänicke RU, Korf HW, von Gall C. Does timing matter in radiotherapy of hepatocellular carcinoma? An experimental study in mice. Cancer Med 2021;10:7712-25. [PMID: 34545699 DOI: 10.1002/cam4.4277] [Reference Citation Analysis]
3 Zhang A, Yuan L, Lin S, Xu H, Lou M, Xue Y, Xu Y. Symptomatic pituitary metastasis from hepatocellular carcinoma: a case report and literature review. All Life 2021;14:691-8. [DOI: 10.1080/26895293.2021.1955753] [Reference Citation Analysis]
4 Moustafa EM, Rashed LA, El-sebaie MM, Thabet NM, Abdel-rafei MK. Crosstalk between ER-stress and apoptosis in irradiated HepG2 cells with gemcitabine: implication of PI3K/AKT and IκB/NF-κB signaling pathways. Journal of Radiation Research and Applied Sciences 2020;13:144-54. [DOI: 10.1080/16878507.2020.1715569] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Fu H, Zhang Y, Chen Y, Chen J, Chen P. CSN1 facilitates proliferation and migration of hepatocellular carcinoma cells by upregulating cyclin A2 expression. Mol Med Rep 2021;23:46. [PMID: 33200803 DOI: 10.3892/mmr.2020.11684] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Lee SJ, Kim M, Kwak YK, Kang HJ. MRI-guided radiotherapy for PVTT in HCC patients: evaluation of the efficacy and safety. J Cancer Res Clin Oncol 2021. [PMID: 34490584 DOI: 10.1007/s00432-021-03788-z] [Reference Citation Analysis]
7 Hong J, Cao L, Xie H, Liu Y, Yu J, Zheng S. Stereotactic body radiation therapy versus radiofrequency ablation in patients with small hepatocellular carcinoma: a systematic review and meta-analysis. Hepatobiliary Surg Nutr 2021;10:623-30. [PMID: 34760966 DOI: 10.21037/hbsn.2020.03.15] [Reference Citation Analysis]
8 Masuda S, Tsukiyama T, Minagawa Y, Koizumi K, Kako M, Kinbara T, Haruki U. Hepatocellular carcinoma effective stereotactic body radiotherapy using Gold Anchor and the Synchrony system: Two case reports and review of literature. World J Clin Cases 2022; 10(8): 2591-2603 [DOI: 10.12998/wjcc.v10.i8.2591] [Reference Citation Analysis]
9 Wang L, Wang W, Rong W, Li Z, Wu F, Liu Y, Zheng Y, Zhang K, Siqin T, Liu M, Chen B, Wu J. Postoperative adjuvant treatment strategy for hepatocellular carcinoma with microvascular invasion: a non-randomized interventional clinical study. BMC Cancer 2020;20:614. [PMID: 32611327 DOI: 10.1186/s12885-020-07087-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
10 Ho YJ, Chang J, Yeh KT, Gong Z, Lin YM, Lu JW. Prognostic and Clinical Implications of WNK Lysine Deficient Protein Kinase 1 Expression in Patients With Hepatocellular Carcinoma. In Vivo 2020;34:2631-40. [PMID: 32871793 DOI: 10.21873/invivo.12081] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Manzar GS, De BS, Abana CO, Lee SS, Javle M, Kaseb AO, Vauthey J, Tran Cao HS, Koong AC, Smith GL, Taniguchi CM, Holliday EB, Das P, Koay EJ, Ludmir EB. Outcomes and Toxicities of Modern Combined Modality Therapy with Atezolizumab Plus Bevacizumab and Radiation Therapy for Hepatocellular Carcinoma. Cancers 2022;14:1901. [DOI: 10.3390/cancers14081901] [Reference Citation Analysis]
12 Chen YS, Sun R, Chen WL, Yau YC, Hsu FT, Chung JG, Tsai CJ, Hsieh CL, Chiu YM, Chen JH. The In Vivo Radiosensitizing Effect of Magnolol on Tumor Growth of Hepatocellular Carcinoma. In Vivo 2020;34:1789-96. [PMID: 32606148 DOI: 10.21873/invivo.11973] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
13 Yadav P, Mimansa, Munawara R, Kapoor K, Chaturvedi S, Kailasam K, Biswas SK, Bahadur D, Srivastava R, Mishra AK, Shanavas A. Nontoxic In Vivo Clearable Nanoparticle Clusters for Theranostic Applications. ACS Biomater Sci Eng 2022;8:2053-65. [PMID: 35416030 DOI: 10.1021/acsbiomaterials.1c01579] [Reference Citation Analysis]
14 Zhang C, Yang M, Ericsson AC. The Potential Gut Microbiota-Mediated Treatment Options for Liver Cancer. Front Oncol 2020;10:524205. [PMID: 33163393 DOI: 10.3389/fonc.2020.524205] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
15 Farzaneh Z, Vosough M, Agarwal T, Farzaneh M. Critical signaling pathways governing hepatocellular carcinoma behavior; small molecule-based approaches. Cancer Cell Int 2021;21:208. [PMID: 33849569 DOI: 10.1186/s12935-021-01924-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Yang KL, Chi MS, Ko HL, Huang YY, Huang SC, Lin YM, Chi KH. Axitinib in combination with radiotherapy for advanced hepatocellular carcinoma: a phase I clinical trial. Radiat Oncol 2021;16:18. [PMID: 33472666 DOI: 10.1186/s13014-020-01742-w] [Reference Citation Analysis]
17 Chen LC, Lin HY, Hung SK, Chiou WY, Lee MS. Role of modern radiotherapy in managing patients with hepatocellular carcinoma. World J Gastroenterol 2021; 27(20): 2434-2457 [PMID: 34092968 DOI: 10.3748/wjg.v27.i20.2434] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
18 Gao Y, Lyu L, Feng Y, Li F, Hu Y. A review of cutting-edge therapies for hepatocellular carcinoma (HCC): Perspectives from patents. Int J Med Sci 2021;18:3066-81. [PMID: 34400877 DOI: 10.7150/ijms.59930] [Reference Citation Analysis]